Prof Nancy Devlin

Text: ‘Publication, Paper Tuesday - Valuing health states for infants and toddlers: challenges and methodological considerations in EQ-TIPS preferences elicitation. by Devlin, N. et al. (2025).' The background is a gradient blue with overlaid images of books and the world map.

EQ-TIPS was developed to meet growing interest in evaluating the effectiveness & cost-effectiveness of treatments in very young children 👶

In this paper, @prof-nancy-devlin.bsky.social et al. examine issues in valuing the EQ-TIPS and possible adaptations to valuation methods 👉 bit.ly/4oxl4gF

in a good way, though, I hope! :-)

Highlight points from a new paper summarising established and new tools for measuring and valuing health related quality of life, developed by a not for profit organisation called the EuroQol Research Foundation.

New paper: "Measuring & Valuing Health Using EuroQol Instruments: New Developments 2025 and Beyond"

▶️open access: tinyurl.com/EuroQol2025u...

@fengtastic.bsky.social @beaunebeaune.bsky.social @ellystolk.bsky.social

#HealthEconomics #PROMS #HRQOL #EQ-5D #EQ-5D-Y #EQ-HWB-9 #EQ-TIPS #Bolt-ons

Thanks @frasermorton.bsky.social for adding the Australian value set for the EQ-5D-Y-3L to your #rstats #EQ5D package! That was quick work!

@euroqol.bsky.social @rich-norman.bsky.social
Our paper is available here, open access:
➡️https://tinyurl.com/AussieY-3Lvalueset

I'm looking forward to the 2025 #iHEA Congress, & the pre-congress @euroqol.bsky.social session.

Authors: If you're presenting a paper at iHEA & thinking of submitting it to #ValueinHealth - drop me a message! I'll do my best to come to your session. Or just come up & say hi!

#healtheconomics #VIH

Image is copyright to Jane Doe/ Shutterstock. Shows a cartoon image of Donald Trump with a signed Executive Order

Will Trump's plan to use 'Reference Pricing' cut US drug prices? This #ValueinHealth paper by Grueger, Martin & Sullivan argues reference pricing is ill-advised & will lead to unintended consequences.

open access 👉 tinyurl.com/reference-pr...

#Trump #HealthEconomics

NHS plans to DNA test all babies in England to assess disease risk Scheme is part of the government's 10-year plan for the NHS in England aimed at easing pressure on services.

News from the English NHS: www.bbc.com/news/article...

#genomics #precisionmedicine
@eigen-uom.bsky.social

just a big yellow-coloured number 6.0

New impact factor for Value in Health. We're chuffed!
#healtheconomics

This letter, in the June issue of Value in Health, makes for pretty interesting reading:
www.valueinhealthjournal.com/article/S109...

#healtheconomics #equity #HTA

Drop the "M": Minimally Important Difference and Change Are Not Independent Properties of an Instrument and Cannot Be Determined as a Single Value Using Statistical Methods - PubMed MID must be estimated within a specific study context. It is best to think of PRO measures in terms of "ID" and leave the "M" to case-by-case, context-based interpretation.

New Value in Health paper, "Drop the M", of interest to anyone struggling with how to interpret data from patient reported outcome measures, and what a Minimally Important Difference means. Authors: Vickers, Nolla & Cella.
👉 pubmed.ncbi.nlm.nih.gov/40216310/

#HealthEconomics

Thank you!! 👍

Hey @altmetric.com, I was wondering if you've got any updates on this you could share? #AcadmicSky #EconSky

The Public Philosopher Join us for a day of philosophical discussion in honour of Professor Jo Wolff's career.

Two great philosophers retiring. Two conferences to honour them. Two great line ups. Both open to the public. Sign up.
Jo Wolff www.bsg.ox.ac.uk/events/publi...
& Jeff McMahan
www.ccc.ox.ac.uk/alumni/event...

Using patient-reported outcome measures to estimate cost-effectiveness of hip replacements in English hospitals - PubMed Using the new patient-assessed health-related quality of life data combined with routine hospital-level cost data it is possible to estimate a procedure-based measure of efficiency for hospitals. The ...

Nice work @lauratrigg.bsky.social! 🙌 We need to see much more of this kind of evidence on the cost effectiveness of existing healthcare interventions. b.t.w,@jappleby123.bsky.social @koonalshah.bsky.social looked at hip surgery in 2013, using NHS PROMS data: pubmed.ncbi.nlm.nih.gov/23759892/

A powerpoint slide from Prof. Devlin linking the case for CBA to the need for cross-sectoral economic evaluation

Tomorrow at #ISPOR2025: in this 75-min 'spotlight' session we will give in-depth consideration of whether Cost Benefit Analysis could play a bigger role in HTA. If you are here in Montreal, I hope to see you there!
#HealthEconomics

Health inequalities - an update to NICE’s methods for health technology evaluation

An update on NICE methods regarding health inequalities in health technology evaluations is out now:

tinyurl.com/NICEmethodsh...

#HealthEconomics

@euroqol.bsky.social puts out these useful posts regularly, where they do a quick ‘round-up ’ of new papers published about EQ-5D and related instruments. I find therir posts very helpful. If you’re interested in HRQoL, utilities etc, it’s worth following them!
#HealthEconomics #PROMs

#ISPORAnnual Virginia Acha notes that tough pricing regulation in the US will reduce incentives for investment in innovation - and this is a double whammy if coupled with reduced US funding of basic science.
#referencepricing #HealthEconomics

At ISPOR 2025 Darius Lakdawalla: some form of price intervention is now inevitable in the US, hopefully based on value, and done in a ‘US specific way’. Time for the US to adopt its own HTA.

At today’s ISPOR conference: Sean Sullivan arguing US reference pricing is ‘lazy and misguided’ - but has bipartisan support.

Drug price cuts: what is Trump planning and what will it mean for big pharma? President has directed Robert Kennedy to send price targets to industry, with slimming drugs thought to be included

I'm guessing this is going to be a hot topic of conversation here at ISPOR Montreal over the coming days!
www.theguardian.com/business/202...
#HealthEconomics

Trump to sign executive order on reducing prescription drug prices U.S. President Donald Trump said on Sunday he would sign an executive order that he said would reduce prescription drug and pharmaceutical prices by between 30% and 80%.

Will the US introduce 'reference pricing'?
www.reuters.com/business/hea...

[2/2] So, after the 10-year exclusivity period ends, what happens? Not much: despite expectations of price reductions, the authors observe that many orphan meds seem to lack competition.
@amsterdamumc.bsky.social

This 'Editor's Choice' paper is available open access: tinyurl.com/EUOrphanMeds

abstract of a new paper just published in Value in Health, May 2025, Twenty-Four Years After the Launch of the EU Orphan Regulation: Analyzing Dutch Price Dynamics, Biosimilars, and Generics for Orphan Medicinal Products

[1/2] "24 yrs After the Launch of the EU Orphan Regulation: Analyzing Dutch Price Dynamics, Biosimilars & Generics for Orphan Medicinal Products"by Sibren van den Berg & colleagues in the May issue of Value in Health @amsterdamumc.bsky.social

👉 tinyurl.com/EUOrphanMeds
#HealthEconomics

abstract of a new paper in Value in Health, May 2025, by Mireia Jofre-Bonet and colleagues about the effect of biosimilars on prices in the US

"The Price Effects of Biosimilars In the US" by Mireia Jofre-Bonet et al. concludes the US biosimilars market has become highly competitive; driving price reductions between 2015-2023 with substantial savings for Medicare

➡️ tinyurl.com/PriceEffects...

@ohenews.bsky.social
#HealthEconomics

highlight points from a paper published in Value in Health, looking at how well women are represented in authorship of papers submitted and accepted by the journal.

Are women under-represented in publishing in #HealthEconomics? We did an analysis of submissions and acceptances to Value in Health. Results are quite encouraging - but still scope for improvement.

open access paper here: tinyurl.com/WomenAuthors...

screenshot of an editorial in the May 2025 issue of Value in Health. The paper discussed what the term 'Whole Health' means and discuses some of the implications for how we evaluate costs and benefits.

What is 'Whole Health' and what does it mean for approaches to economic evaluation? The new issue of Value in Health has articles on this from US CDC, WHO & ISPOR, and this little editorial from me & fellow editors Daniel Mullins & Pieter van Baal:

👉 tinyurl.com/WhatDoesWhol...

#HealthEconomics

Photo of author and researcher Mary Ziegler being interviewed on CNN about her new book, 'Personhood: the new civil war over reproduction'.

I love it when someone really interesting is interviewed on the news sitting in front of their bookcase. @maryrziegler.bsky.social's new book, 'Personhood: The New Civil War Over Reproduction' now added to my reading list. @cnn.com

#universitychallenge | Chloë Hardern | 16 comments Health economics spotted in the wild… did anyone else get 100%? 💅 #universitychallenge | 16 comments on LinkedIn

When QALYs, VAS and standard gamble make it onto TV...
tinyurl.com/38xvf8vy

Indiana state legislature just staged a hostile takeover of IU, functionally eliminating tenure, promising to close smaller (hum) majors, taking over the IU board, and cutting the IU budget. This is so bleak